Fig. 7
From: Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
Anti-PD-1 antibody combined with cisplatin inhibited tumor growth without reducing the number of Treg cells. Tumors were harvested from a subset of K7M2 tumor-bearing mice on day 27 following tumor cell injection. Ten days after inoculation, mice were treated intraperitoneally with PBS (100 ul/rat), 5 mg/kg cisplatin, 1 mg/kg anti-PD-1 antibody, and cisplatin (5 mg/kg) plus anti-PD-1 antibody (1 mg/kg), once every 3 days, 5 times in total. a, b Mean tumor volumes in each group (n = 4). c Treg cells were analyzed by flow cytometry (n = 4/group). The experiment was repeated three times. Results are presented as the mean ± standard deviation. **P < 0.01 vs. the control group. PD-1, programmed cell death protein; Treg, regulatory T